Agile Therapeutics (AGRX) Trading 7.9% Higher

Agile Therapeutics Inc (NASDAQ:AGRX)’s share price traded up 7.9% on Thursday . The stock traded as high as $0.97 and last traded at $0.96. 656,956 shares traded hands during trading, a decline of 62% from the average session volume of 1,731,310 shares. The stock had previously closed at $0.89.

Several equities analysts have recently weighed in on the stock. HC Wainwright set a $4.00 price objective on shares of Agile Therapeutics and gave the company a “buy” rating in a report on Tuesday, October 9th. ValuEngine upgraded shares of Agile Therapeutics from a “sell” rating to a “hold” rating in a report on Friday, August 3rd. Three research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The stock has an average rating of “Buy” and a consensus target price of $4.00.

The firm has a market cap of $30.77 million, a price-to-earnings ratio of -1.10 and a beta of -0.95.

Agile Therapeutics (NASDAQ:AGRX) last announced its quarterly earnings data on Thursday, November 1st. The specialty pharmaceutical company reported ($0.11) earnings per share for the quarter, beating the consensus estimate of ($0.15) by $0.04. On average, analysts expect that Agile Therapeutics Inc will post -0.6 earnings per share for the current year.

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Dimensional Fund Advisors LP raised its holdings in shares of Agile Therapeutics by 62.8% during the first quarter. Dimensional Fund Advisors LP now owns 145,070 shares of the specialty pharmaceutical company’s stock valued at $373,000 after purchasing an additional 55,937 shares during the period. Renaissance Technologies LLC raised its holdings in shares of Agile Therapeutics by 76.3% during the second quarter. Renaissance Technologies LLC now owns 792,990 shares of the specialty pharmaceutical company’s stock valued at $392,000 after purchasing an additional 343,290 shares during the period. Finally, Fosun International Ltd acquired a new stake in shares of Agile Therapeutics in the 3rd quarter worth about $180,000. Hedge funds and other institutional investors own 51.92% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This news story was first reported by The Lincolnian Online and is the sole property of of The Lincolnian Online. If you are accessing this news story on another domain, it was stolen and reposted in violation of U.S. and international copyright and trademark law. The legal version of this news story can be accessed at https://www.thelincolnianonline.com/2018/11/10/agile-therapeutics-agrx-trading-7-9-higher.html.

Agile Therapeutics Company Profile (NASDAQ:AGRX)

Agile Therapeutics, Inc, a women's healthcare company, focuses on the development and commercialization of prescription contraceptive products for women. Its lead product candidate is Twirla, also known as AG200-15, a once-weekly prescription combination hormonal contraceptive patch, which completed Phase III clinical trials.

Featured Story: Dollar Cost Averaging

Receive News & Ratings for Agile Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agile Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply